Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
241-255 of 362

Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CEMaximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices

Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CEChairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CEPatient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities

First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study

Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
- advertisement

Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC

Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence

Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence

Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
- advertisement

The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®The Evolving Treatment Landscape for MBC: Emerging Therapies

Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®Management of HER2-Low MBC Following First-Line Disease Progression






























